Study supports Innogenetics' tests for AD (Alzheimer's disease)
This article was originally published in Clinica
Executive Summary
The combination of two cerebrospinal fluid (CSF)-based tests for Alzheimer's disease (AD) can confirm or rule out the disease with an accuracy of more than 90%, according to a Swedish study. The researchers say that the tests, which detect levels of beta-amyloid-42 peptide and tau protein respectively, should be included in the clinical work-up of patients with cognitive impairment, especially to differentiate early AD from normal ageing and psychiatric disorders.